Acadia Pharma press release (NASDAQ:ACAD): Q4 GAAP EPS of $0.28 misses by $0.02. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce earnings results on Tuesday, February 27th, after market
Summary: ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of
Summary: Shares of Acadia Pharmaceuticals surged after the Court granted a summary judgment in the
Summary: Acadia’s Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million
Summary: Acadia Pharmaceuticals’ gains recently disappeared despite the strong launch of Daybue. Poor market conditions
Summary: Acadia Pharmaceuticals shows fiscal resilience with a shift to net positive income, buoyed by
Summary: Acadia Pharmaceuticals’ stock rose 20% after expanding rights to Rett syndrome drug Daybue, with
Summary: Acadia’s Q1 2023 financials demonstrate marginal improvement when compared to the same period in
Summary: Shares of Acadia Pharmaceuticals Inc. have been stuck in a range for the last